Perspectum’s Digital Biliary Tree Viewer, MRCP+ Receives FDA Clearance Announces Perspectum Diagnostics

Section 2

Northwell Health Sends Vaccinators to Ecuador

At the request of Ecuador’s Minster of Health, and for the first time since the start of the pandemic, the Northwell Health CGH team traveled outside of the U.S. on June 13 to help get shots in arms relieve overburdened health care workers in the South American country who have been working around the clock in the race to vaccinate their population.

Fusion Marketplace Changes Healthcare Traveler Experience

Fusion Marketplace is a traveler-first driven platform giving healthcare professionals the power to make decisions in their careers that they haven't been able to in the past.

MRCP+, the worlds most advanced biliary visualization software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).  The news was announced today by Perspectum Diagnostics

Perspectum has developed quantitative MRI and AI algorithms for MRCP images to provide improved visualization of intra-hepatic ducts and measure the widths of bile ducts, biliary tree volume and gallbladder volume. Combining image viewing, processing, and reporting tools, the metrics provided are designed to support physicians in the visualization, evaluation, monitoring, and reporting of hepatobiliary structures. This is especially relevant for serial evaluation in PSC patients.

“I am excited by the FDA clearance of MRCP+. Non-invasive MRCP+ detection of both the numbers and diameters of strictures in patients with PSC has the potential to become a primary end point for therapeutic trials in PSC, a disease for which no effective treatments exist,” commented John M Vierling, Professor of Medicine and Surgery, Baylor College of Medicine, Former President, American Association for the Study of Liver Diseases.

The diagnosis of PSC is hindered by lack of effective biomarkers. Interpretation of conventional MRCPs itself is both qualitative and subject to relatively low inter-operator reliability. Perspectum worked closely with patients with biliary disease to design and validate the software, scanning over 140 patients. MRCP+ has shown diagnostic potential for PSC in a study released at AASLD The Liver Meeting 2018 and is being evaluated for acute biliary imaging later this year.

Martine Walmsley, Chair of Trustees for PSC Support: “The ability to diagnose and monitor the progression of PSC is needed to help develop new treatments, improve methods for cancer surveillance and allow the early management of symptoms and complications of PSC. To this end we welcome the clearance of MRCP+ which will provide additional information for clinicians and researchers, helping address unmet need for patients with PSC.”

MRCP+ is already cleared for clinical use in Europe, with CE-marking. It can process data from all 1.5T and 3T GE, Siemens and Philips MR scanners that support 3D MRCP sequences, providing standardized quantitative metrics for the pancreatobiliary system. MRCP+ is safe, non-invasive, involves no contrast, and a typical scan takes less than 15 minutes, with same day results.

Professor Sir Michael Brady, Executive Chairman of NCIMI and Founder, Chairman and Image Analysis Lead of Perspectum Diagnostics, “Perspectum develops quantitative MRI for decision support in a range of diseases in the liver and related organs. MRCP+ is one of the first examples of AI in medical imaging being used to solve unmet needs in hepatobiliary medicine.”

MRCP+ will be formally launched at EASL 2019, 12th April 6.30 – 7.30pm.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles